Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PLX7486 |
Synonyms | |
Therapy Description |
PLX7486 binds to and inhibits CSF1R, TRKA, TRKB, and TRKC, which potentially results in decreased tumor cell proliferation (PMID: 28174090). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PLX7486 | PLX 7486|PLX-7486 | CSF1R Inhibitor 28 Trk Receptor Inhibitor (Pan) 32 | PLX7486 binds to and inhibits CSF1R, TRKA, TRKB, and TRKC, which potentially results in decreased tumor cell proliferation (PMID: 28174090). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01804530 | Phase I | PLX7486 Gemcitabine + Nab-paclitaxel | Phase 1 Study of PLX7486 as Single Agent and With Gemcitabine Plus Nab-Paclitaxel in Patients With Advanced Solid Tumors | Terminated | USA | 0 |